Genzyme Corporation (NASDAQ: GENZ) is an American biotechnology company based in Cambridge, Massachusetts. Genzyme is the world’s third-largest biotechnology company, employing more than 11,000 people around the world. The company has a presence in approximately 40 countries, including 17 manufacturing facilities and 9 genetic-testing laboratories, its products are sold in 90 countries. In 2007, Genzyme generated $3.8 billion in revenues with more than 25 products in the market. In 2006 and 2007 Genzyme was named one of Fortune Magazine’s “100 Best Companies to Work for”. The company donated $83 million worth of products worldwide; in 2006, it made $11 million in cash donations. In 2005, Genzyme was awarded the National Medal of Technology, the highest level of honor awarded by the president of the United States to America’s leading innovators.
Figures are based on itemized contributions reported to the Federal Election Commission and state agencies. Please note that:
- contributions under $200 are not reported, and so are not included in totals.
- only contributions from individuals and organizations to candidates are included. Various accounting measures and more exotic contribution types are excluded.
- contributions are matched based on organization and recipient name reported within each election cycle. Contributions using an incorrect or non-standard version of the name may be missed.
- corporate name changes and mergers may cause figures to differ from those of the Center for Responsive Politics.
- organization totals include known subsidiaries of the organization.
Latest FEC Datacovers through committee's December 31, 2012 filing.
Summaryoverview of the committee's finances
- Total Raised:
- Total Spent:
- Cash on Hand:
Standardized Donation Informationcovers roughly through Q4 2012. may lag behind FEC section above, as donors and industries are identified by hand.
- Employee Color Block
- PAC Color Block
Republicans vs. Democratsin dollars
State vs. Federalin dollars
Top PAC Recipients
- Employee Color Block
- PAC Color Block
Figures are based on lobbying activity reported to the Senate Office of Public Records. Reported dollar amounts are required to be accurate only to the nearest $20,000. For organizations whose primary business is lobbying, we display total income and top clients. For organizations that are not primarily lobbying firms, we display total amount spent on lobbying and top lobbying firms hired.
For more information, please see our lobbying methodology page.
Lobbying on Behalf of Genzyme Corp
Names of Lobbyists
Firm Hired Amount Genzyme Corp $3,115,040
Most Frequently Disclosed Lobbying Issues
- Health Issues,
- Medicare & Medicaid,
- Fed Budget & Appropriations,
- Copyright, Patent & Trademark,
Most Frequently Disclosed Bills
Bill No. Title S.296 Preserving Access to Life-Saving Medications Act H.R.2245 Preserving Access to Life-Saving Medications Act of 2011 H.R.2608 Small Business Program Extension and Reform Act of 2011 H.CON.RES.112 Establishing the budget for the United States Government for fiscal year 2013 and setting forth appropriate budgetary levels for fiscal years 2014 through 2022. S.365 Budget Control Act of 2011 S.606 Creating Hope Act of 2011 H.R.2017 Continuing Appropriations Act, 2012 S.23 Patent Reform Act of 2011 H.R.1249 America Invents Act H.R.3630 Middle Class Tax Relief and Job Creation Act of 2011
RegulationsMentioned in 23 dockets
All data is based on documents downloaded from Regulations.gov. The first table shows mentions: all documents that include the name of the company anywhere in the document or document metadata. The second table shows submissions: all documents where the submitter metadata included the company name. Each table shows the top 10 dockets, ranked by number of occurrences.
Matches are based on a search for the company name. Variations in the company name, such as acronyms, nicknames or alternate names may cause documents to be missed. The mention of a company name in a document may be incidental and does not necessarily indicate that the company has any relevance to the document. Company names that are common English words may erroneously match with text that is not referring to the company.
Not all agencies submit public comments to Regulations.gov. For a list of participating and non-participating agencies see here. Agencies that do submit to Regulations.gov have varying levels of accuracy and completeness.
Regulations and public comments can be downloaded in bulk here.
The tables show occurrences of "Genzyme Corp" in public comments on proposed federal regulations.
Mentions in Document Text
View all mentions data for Genzyme Corp
- Toggle 8 FDA Allocate Full Doses of Agalsidase Beta (Fabrazyme®) to U.S. Citizens Under its Consent Decree with Genzyme Corporation 2011
- Toggle 3 FDA Request That FDA Confirm the Agency Will Stay Approval of Abbreviated New Drug Application No. 90-363, for 30 Months Beginning on June 23, 2009 - CLOSED 2011
- Toggle 3 CPSC Poison Prevention Packaging Requirements: Proposed Exemption of Powder Formulations of Colesevelam Hydrochloride and Sevelamer Carbonate 2011
- Toggle 3 EBSA PTE 2012-0008 Genzyme Corporation 401(k) Plan (the Plan or the Applicant) [Application No. D–11669] 2012
- Toggle 2 FDA Advisory Committee, Workshops, and Conferences Notices Various Meeting Notices (eg., Task Force Meeting, etc.) 2012
- Toggle 2 EBSA PTE 2012-06 Retirement Program for Employees of EnPro Industries (Plan) [Application No. D–11662] 2012
- Toggle 2 EBSA PTE 2012-04 Aztec Well Servicing Company & Related Companies Medical Plan Trust Fund (the Plan) [Application No. D–11628] 2012
- Toggle 1 FDA Patent Term Extension Application for Gel-One® (sodium hyaluronate), US. Patent No. 6,602,859 2011
- Toggle 1 CMS Medicare Program; Payment Policies Under the Physician Fee Schedule and Other Revisions to Part B for CY 2012 2011
- Toggle 1 NHTSA Environmental Impact Statement for Corporate Average Fuel Economy (CAFE)Standards, Model Years 2017-2025 2011